Walking into the future: How Wandercraft is restoring mobility with AI and compassion

At ballas invest, we back bold companies reshaping the future of healthcare, and Wandercraft exemplifies that mission. This Paris-based deeptech startup is reinventing mobility for people with disabilities through its self-balancing exoskeleton. In 2024, Wandercraft gained global momentum with rapid European adoption, regulatory wins in the U.S., and widespread recognition across tech and medtech communities. As we look to 2025, the company's expansion into personal-use devices signals not just a new market, but a new era for digital health.

Innovation that walks the talk

Wandercraft's core product, Atalante X, is the world’s first hands-free, self-balancing exoskeleton. It allows individuals with spinal cord injuries, stroke, and neurodegenerative diseases to stand and walk again—without crutches or external support. Unlike conventional exoskeletons, Atalante uses proprietary AI-driven algorithms and real-time motion adaptation to mimic natural human gait. This radically changes what's possible in rehab settings, enabling patients to practice real-world tasks like reaching, turning, and balancing.

This isn’t innovation for the sake of tech. It’s a solution born from engineering rigor and clinical need. Hundreds of patients in Europe are already using Atalante in top-tier rehab centers. In France, Wandercraft became a symbol of inclusion when a paraplegic athlete carried the Olympic torch using the device. These moments are powerful because they reveal what this technology is ultimately about: restoring independence and dignity.

From Hospitals to Homes: The Next Leap

In 2025, Wandercraft will launch clinical trials in the U.S. for its Personal Exoskeleton—a wearable, everyday mobility device. This next-gen model builds on the company’s core self-balancing tech but is designed for home and community use. If successful, it will open access to millions of individuals currently underserved by mobility solutions. With FDA clearances already secured for hospital use, the company is well-positioned to become a dominant force in both rehab and personal mobility.

Why this matters for Healthcare: Wandercraft restoring mobility

From an investment perspective, Wandercraft sits at the intersection of high-impact innovation and scalable healthtech opportunity. It addresses a massive unmet need: 15 million people worldwide live with spinal cord injuries, 62 million with stroke aftereffects, and hundreds of thousands with diseases like ALS. Conventional care is costly and labor-intensive; Wandercraft offers a new path.

Its tech reduces therapist workload, shortens rehab timelines, and improves clinical outcomes. For patients, it’s a step toward autonomy. For hospitals and insurers, it’s an opportunity to improve efficiency. And for the broader digital health ecosystem, it’s proof that robotics and AI can deliver truly life-changing care.

Recognition that signals readiness

In early 2025, Wandercraft was featured in NVIDIA’s CES keynote and won the SXSW Innovation Award for AI. These are not just accolades—they’re validation. They highlight how Wandercraft’s technology stands at the convergence of digital health, advanced robotics, and compassionate patient focused innovation. It’s no longer about what’s possible; it’s about scaling what’s proven.

ballas invest's Perspective

We believe in Wandercraft’s mission in restoring mobility to countless patients, and we’re proud to support a team that consistently puts patients first. Their work demonstrates that when visionary engineering meets healthcare purpose, the results can be transformative. As the company moves into the U.S. market and toward personal mobility devices, we see an inflection point not only for Wandercraft but for the future of movement itself.

Wandercraft is not just building exoskeletons. It is restoring movement, dignity, and hope.

That’s the kind of innovation we invest in.

Read more about recent news and achievements on their website Wandercraft